1
|
Watanabe S, Yogo A, Otsubo T, Umehara H, Oishi J, Kodo T, Masui T, Takaishi S, Seno H, Uemoto S, Hatano E. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. BMC Cancer 2022; 22:489. [PMID: 35505283 PMCID: PMC9063137 DOI: 10.1186/s12885-022-09619-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Accepted: 04/25/2022] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Pancreatic cancer is one of the most lethal tumors. The aim of this study is to provide an effective therapeutic discovery platform for pancreatic cancer by establishing and characterizing patient-derived organoids (PDOs). METHODS PDOs were established from pancreatic tumor surgical specimens, and the mutations were examined using a panel sequence. Expression of markers was assessed by PCR, immunoblotting, and immunohistochemistry; tumorigenicity was examined using immunodeficient mice, and drug responses were examined in vitro and in vivo. RESULTS PDOs were established from eight primary and metastatic tumors, and the characteristic mutations and expression of cancer stem cell markers and CA19-9 were confirmed. Tumorigenicity of the PDOs was confirmed in subcutaneous transplantation and in the peritoneal cavity in the case of PDOs derived from disseminated nodules. Gemcitabine-sensitive/resistant PDOs showed consistent responses in vivo. High throughput screening in PDOs identified a compound effective for inhibiting tumor growth of a gemcitabine-resistant PDO xenograft model. CONCLUSIONS This PDO-based platform captures important aspects of treatment-resistant pancreatic cancer and its metastatic features, suggesting that this study may serve as a tool for the discovery of personalized therapies.
Collapse
Affiliation(s)
- Sadanori Watanabe
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan.
| | - Akitada Yogo
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tsuguteru Otsubo
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan
| | - Hiroki Umehara
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan
| | - Jun Oishi
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan
| | - Toru Kodo
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan
| | - Toshihiko Masui
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
| | - Shigeo Takaishi
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Hiroshi Seno
- DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shinji Uemoto
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Etsuro Hatano
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
2
|
Yoshinaga H, Masumoto S, Koyama K, Kinomura N, Matsumoto Y, Kato T, Baba S, Matsumoto K, Horisawa T, Oki H, Yabuuchi K, Kodo T. Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT1A weak partial agonistic activity showing the antidepressant-like effect. Bioorg Med Chem 2017; 25:293-304. [DOI: 10.1016/j.bmc.2016.10.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 10/25/2016] [Accepted: 10/28/2016] [Indexed: 11/15/2022]
|
3
|
Fukaya T, Kodo T, Ishiyama T, Nishikawa H, Baba S, Masumoto S. Design, synthesis and structure–activity relationship of novel tricyclic benzimidazolone derivatives as potent 18kDa translocator protein (TSPO) ligands. Bioorg Med Chem 2013; 21:1257-67. [DOI: 10.1016/j.bmc.2012.12.024] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2012] [Revised: 12/17/2012] [Accepted: 12/18/2012] [Indexed: 10/27/2022]
|
4
|
Katayama S, Ae N, Kodo T, Masumoto S, Hourai S, Tamamura C, Tanaka H, Nagata R. Tricyclic indole-2-carboxylic acids: highly in vivo active and selective antagonists for the glycine binding site of the NMDA receptor. J Med Chem 2003; 46:691-701. [PMID: 12593650 DOI: 10.1021/jm020239l] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A series of tricyclic indole-2-carboxylic acid derivatives were synthesized and evaluated by the radioligand binding assay and the anticonvulsant effects in the mouse NMDA-induced seizure model. Among them, derivatives of 3S-(-)-4 such as 3a, 3f, and 3g which had certain zwitterionic anilides showed high affinity to the NMDA-glycine binding site. The absolute configuration of 3S-(-)-4 was confirmed by X-ray crystallographic analysis. In particular, 3g (SM-31900) was found to be a highly active glycine antagonist for both in vitro and in vivo assays (K(i) = 1.0 +/- 0.1 nM, ED(50) = 2.3 mg/kg, iv) and also showed high selectivity for the glycine site. In addition, 3g was soluble enough in aqueous media (>10 mg/mL at pH 7.4) to use for medications by intravenous injection.
Collapse
MESH Headings
- Animals
- Anticonvulsants/chemical synthesis
- Anticonvulsants/pharmacokinetics
- Anticonvulsants/pharmacology
- Binding Sites
- Binding, Competitive
- Brain/drug effects
- Brain/metabolism
- Brain/pathology
- Brain Infarction/drug therapy
- Brain Infarction/etiology
- Brain Infarction/pathology
- Crystallography, X-Ray
- Glycine/metabolism
- Heterocyclic Compounds, 3-Ring/chemical synthesis
- Heterocyclic Compounds, 3-Ring/chemistry
- Heterocyclic Compounds, 3-Ring/pharmacology
- Indoles/chemical synthesis
- Indoles/chemistry
- Indoles/pharmacokinetics
- Indoles/pharmacology
- Infarction, Middle Cerebral Artery/complications
- Infarction, Middle Cerebral Artery/drug therapy
- Infarction, Middle Cerebral Artery/pathology
- Mice
- Models, Molecular
- Neuroprotective Agents/chemical synthesis
- Neuroprotective Agents/pharmacokinetics
- Neuroprotective Agents/pharmacology
- Radioligand Assay
- Rats
- Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
- Receptors, N-Methyl-D-Aspartate/metabolism
- Seizures/drug therapy
- Solubility
- Stereoisomerism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Seiji Katayama
- Research Division, Sumitomo Pharmaceuticals Co., Ltd, 1-98 Kasugadenaka 3-chome, Konohana-ku, Osaka 554-0022, Japan
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Nagata R, Tanno N, Kodo T, Ae N, Yamaguchi H, Nishimura T, Antoku F, Tatsuno T, Kato T, Tanaka Y. Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de] quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de] quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor. J Med Chem 1994; 37:3956-68. [PMID: 7966156 DOI: 10.1021/jm00049a015] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A series of tricyclic quinoxalinediones, 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones, were synthesized and was evaluated for their affinity for the glycine binding site of the NMDA receptor using a [3H]-5,7-dichlorokynurenic acid binding assay. The six-membered ring-fused tricyclic quinoxalinedione 18g (Ki = 9.9 nM) displayed high affinity for the glycine site. The anilide derivative 20g (Ki = 2.6 nM) was 4-fold more potent than 18g and as potent as L-689,560, one of the most potent glycine antagonists so far prepared. Although the carboxylic acid derivative of the corresponding five-membered ring-fused tricyclic quinoxalinedione 18e (Ki = 7.3 nM) had affinity comparable to that of 18g, the anilide derivative 20e largely decreased in the affinity in contrast to 20g. Enantiomers 23g, 24g, 25g, and 26g were prepared and tested. Only the S enantiomer 25g (Ki = 0.96 nM) retained the affinity among the anilide derivatives, whereas both enantiomers 23g (Ki = 2.3 nM) and 24g (Ki = 9.6 nM) were active among the carboxylic acid derivatives. The origin of the high affinity of carboxylic acid derivatives such as 18e and 18g would be a charge-charge interaction between the anionic carboxylate residues of the compounds and the cationic proton-donor site in the receptor.
Collapse
Affiliation(s)
- R Nagata
- Sumitomo Pharmaceuticals Research Center, Osaka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Hamanoue K, Nakayama T, Nanshow H, Hanada T, Naruta Y, Kodo T, Maruyama K. Photoinduced intramolecular charge separation in an anthraquinone-linked all-cis 5, 10, 15, 20-meso-tetrakis (2-aminophenyl)porphyrin derivative studied by picosecond and nanosecond laser spectroscopy. ACTA ACUST UNITED AC 1993. [DOI: 10.1039/ft9938903243] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|